CMS Sticks To Its Original Thinking In Final VAD Coverage Decision
This article was originally published in The Gray Sheet
Executive Summary
The agency’s Oct. 31 national coverage determination for ventricular assist devices differs little from the August proposal – a result that analysts are speculating could benefit VAD maker Thoratec and potentially disadvantage HeartWare.
You may also be interested in...
CMS Fields Many Suggestions And Criticisms On Proposed VAD Policy
Several stakeholders are still pushing CMS to recognize “bridge-to-decision” heart failure patients who may eventually be suitable for a heart transplant but are not so at the time they receive a ventricular assist device.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.